Keppra

How Does Keppra Work?

Keppra (levetiracetam) works through a unique mechanism: it binds to synaptic vesicle glycoprotein 2A (SV2A), a protein found on tiny sacs inside neurons that store neurotransmitters. By binding to SV2A, levetiracetam modulates the release of neurotransmitters at synapses, dampening abnormal neuronal firing patterns that cause seizures.

This mechanism is completely different from other anti-seizure medications, which typically work by blocking sodium or calcium ion channels or by enhancing GABA (gamma-aminobutyric acid) activity. Levetiracetam does not work through these pathways, which is why it is often effective in patients who have not responded to other seizure medications. As of 2024, SV2A modulation is widely accepted as levetiracetam's primary mechanism of action.

From a pharmacokinetics perspective, levetiracetam is rapidly absorbed (peak levels in ~1 hour), minimally protein-bound (<10%), and primarily excreted unchanged by the kidneys (~66%). This means it has minimal liver metabolism (only ~2.5% through CYP450 enzymes), contributing to its low drug interaction profile. The plasma half-life is approximately 6–8 hours in adults.

How Hard Is It to Find Keppra in Stock?

As of 2026, Keppra (levetiracetam) is not on the FDA's official drug shortage list. The U.S. supply is generally stable, with multiple generic manufacturers producing all tablet strengths, oral solution, and extended-release formulations. medfinder gives levetiracetam a findability score of 78/100 — meaning it is generally available at most pharmacies with only minor, localized stock gaps.

However, localized stock gaps do occur — especially for specific tablet strengths (250 mg and 750 mg are less commonly stocked than 500 mg and 1000 mg) and for the extended-release (XR) formulation. A 2024 UK survey found 62.8% of epilepsy patients had experienced levetiracetam access difficulties at some point, even without an official shortage declaration. Patients should fill prescriptions early and know how to search multiple pharmacies.

If you're having trouble finding Keppra at your usual pharmacy, medfinder calls pharmacies near you to check current stock and texts you the results — saving you from making dozens of calls yourself.

Who Can Prescribe Keppra?

Because Keppra (levetiracetam) is not a controlled substance, any licensed healthcare provider with prescribing authority can prescribe it — there are no special DEA registration requirements or quotas. This makes access broader than many other neurological medications.

Neurologists and epileptologists (primary specialists for new diagnoses and complex cases)

Pediatric neurologists (for children, including infants as young as 1 month)

Primary care physicians (PCPs) — often manage ongoing prescriptions for stable patients

Nurse practitioners (NPs) and physician assistants (PAs)

Emergency physicians (for acute seizure management in hospital settings)

Telehealth prescribing is fully available for levetiracetam — since it is not a controlled substance, there are no federal in-person visit requirements. Telehealth neurology services can manage ongoing epilepsy care and refills remotely, making access easier for patients in rural areas or those with limited mobility. New epilepsy diagnoses typically still require an in-person evaluation with EEG and imaging.

Is Keppra a Controlled Substance?

No. Keppra (levetiracetam) is not a controlled substance and is not scheduled by the DEA. This is a significant advantage compared to some other medications used in neurology — it means there are no DEA quota restrictions on prescribing or dispensing, no special licenses required for prescribers, and no federal limitations on refills or prescription transfers.

Any licensed healthcare provider — including primary care physicians, nurse practitioners, and physician assistants — can prescribe levetiracetam in all 50 states without special DEA registration. It can also be prescribed via telehealth without mandatory in-person visit requirements. Levetiracetam has no known abuse potential or physical dependence profile.

Common Side Effects of Keppra

Common side effects in adults (occurring at least 5% more often than placebo):

Somnolence (drowsiness)

Asthenia (weakness/fatigue)

Dizziness

Headache

Behavioral/mood changes — irritability, aggression (affects ~13% of adults, ~38% of children)

Serious Side Effects (Seek Immediate Care)

DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) — FDA alert issued December 2023; rash with fever and systemic organ involvement

Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis — severe skin reactions; median onset 14–17 days

Anaphylaxis / angioedema — severe allergic reaction, can occur at any time

Suicidal ideation — class-wide FDA warning for all antiepileptic drugs

Final Thoughts on Keppra

Keppra (levetiracetam) is one of the most important and widely used anti-seizure medications available today. Its unique SV2A mechanism of action, favorable safety profile, minimal drug interactions, pregnancy safety data, and affordability as a generic make it a first-line choice for many seizure types across a wide patient population — from infants to elderly patients.

While levetiracetam supply is generally stable in 2026 with no active FDA shortage, localized stock gaps can and do occur. Patients should fill prescriptions early, consider 90-day supply options through mail-order, and be prepared with a contingency plan in case their usual pharmacy is out. With generic pricing as low as $6–$7 per month using discount coupons, cost is manageable for most patients.

If you're having trouble locating Keppra at a pharmacy near you, medfinder calls pharmacies in your area to check current stock and texts you the results. No more driving from pharmacy to pharmacy — find your medication faster and spend more time focused on your health.